This was an open lable, pilot translational clinical pharmacology study of a brief (7 day) course of UFT, 300 mg/m²/day, in combination with leucovorin, 90 mg/day, in six patients with newly diagnosed advanced colorectal cancer.
Gerard Bastian, PhD
Advertisement
Articles by Gerard Bastian, PhD
Tremendous progress has been made in the medical treatment of advanced colorectal cancer during the past 2 to 3 years, due to the availability of several new drugs. Of these new agents, irinotecan (CPT-11 [Camptosar]) seems
Advertisement
Latest Updated Articles
- European Experience With Irinotecan Plus Fluorouracil/Folinic Acid or Mitomycin
Published: August 1st 1998 | Updated:
- Impact of UFT on Tumoral TS and DPD Levels in Colorectal Cancer
Published: October 1st 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
2
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
3
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
4
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
5
